RHT Stock Overview
A healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in Australia, the Asia Pacific, North America, Europe, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Resonance Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.054 |
| 52 Week High | AU$0.086 |
| 52 Week Low | AU$0.038 |
| Beta | 1.38 |
| 11 Month Change | -5.26% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | -50.91% |
| 5 Year Change | -74.88% |
| Change since IPO | 12.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| RHT | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 42.1% | 0.5% | 1.5% |
| 1Y | n/a | 14.2% | 17.2% |
Return vs Industry: Insufficient data to determine how RHT performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how RHT performed against the Australian Market.
Price Volatility
| RHT volatility | |
|---|---|
| RHT Average Weekly Movement | 21.5% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: RHT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: RHT's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Andrew Harrison | www.resonancehealth.com |
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in Australia, the Asia Pacific, North America, Europe, the Middle East, and Africa. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report; and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading. It also provides phantoms for MRI machines.
Resonance Health Limited Fundamentals Summary
| RHT fundamental statistics | |
|---|---|
| Market cap | AU$24.36m |
| Earnings (TTM) | AU$169.30k |
| Revenue (TTM) | AU$8.59m |
143.9x
P/E Ratio2.8x
P/S RatioIs RHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHT income statement (TTM) | |
|---|---|
| Revenue | AU$8.59m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$8.59m |
| Other Expenses | AU$8.42m |
| Earnings | AU$169.30k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.00037 |
| Gross Margin | 100.00% |
| Net Profit Margin | 1.97% |
| Debt/Equity Ratio | 29.0% |
How did RHT perform over the long term?
See historical performance and comparison